Interestingly, the surface expression of therapeutic target TROP2 strongly correlated (r ≥ 0.7) with the surface expression of EpCAM in epithelial-like subpopulation and with SSEA4 in non-tumor hematopoietic/endothelial (FlowSOM.Pop2) or tumor stromal-like (FlowSOM.Pop0) subpopulations both enriched for CD90 and CD9 expression (supplemental Figs. S3D, E and S4A). Here, TACSTD2 is linked to neoplasm.